[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Eslicarbazepine acetate.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eslicarbazepine acetate.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Eslicarbazepine acetate.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Eslicarbazepine acetate.]
[L01BB02, mercaptopurine, Eslicarbazepine acetate may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Eslicarbazepine acetate.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Eslicarbazepine acetate.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Eslicarbazepine acetate.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Eslicarbazepine acetate.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Eslicarbazepine acetate.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Eslicarbazepine acetate.]
[L04AX02, thalidomide, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Eslicarbazepine acetate may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Eslicarbazepine acetate.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Eslicarbazepine acetate.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Eslicarbazepine acetate.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Eslicarbazepine acetate.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Eslicarbazepine acetate.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Eslicarbazepine acetate.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Eslicarbazepine acetate.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Eslicarbazepine acetate.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Eslicarbazepine acetate.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Eslicarbazepine acetate.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Eslicarbazepine acetate.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eslicarbazepine acetate.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Trazodone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Eslicarbazepine acetate.]
[A03AB12, mepenzolate, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Eslicarbazepine acetate.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Trifluperidol.]
[N05AA05, triflupromazine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Eslicarbazepine acetate.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Eslicarbazepine acetate.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Eslicarbazepine acetate.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Eslicarbazepine acetate.]
[A03BB01, butylscopolamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Eslicarbazepine acetate.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Eslicarbazepine acetate.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Eslicarbazepine acetate.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Eslicarbazepine acetate.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Eslicarbazepine acetate.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Eslicarbazepine acetate.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Eslicarbazepine acetate.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Eslicarbazepine acetate.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Eslicarbazepine acetate.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Eslicarbazepine acetate.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Eslicarbazepine acetate.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Eslicarbazepine acetate.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Eslicarbazepine acetate.]
[J05AF01, zidovudine, The metabolism of Eslicarbazepine acetate can be increased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Eslicarbazepine acetate.]
[J05AE02, indinavir, The metabolism of Eslicarbazepine acetate can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Eslicarbazepine acetate.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Eslicarbazepine acetate.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine acetate.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Eslicarbazepine acetate.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Eslicarbazepine acetate.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Eslicarbazepine acetate.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Eslicarbazepine acetate.]
[G04BD07, tolterodine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be decreased when combined with Eslicarbazepine acetate.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Atracurium.]
[S01FA01, atropine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Eslicarbazepine acetate.]
[J01CA09, azlocillin, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Azlocillin.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Eslicarbazepine acetate.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Eslicarbazepine acetate.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Eslicarbazepine acetate.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Eslicarbazepine acetate.]
[J05AE04, nelfinavir, The metabolism of Eslicarbazepine acetate can be increased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Eslicarbazepine acetate.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Eslicarbazepine acetate.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Eslicarbazepine acetate.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Eslicarbazepine acetate.]
[R06AC06, thonzylamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Diethyl ether.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Eslicarbazepine acetate.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Eslicarbazepine acetate.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Eslicarbazepine acetate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Eslicarbazepine acetate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Benperidol.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Eslicarbazepine acetate.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Eslicarbazepine acetate.]
[N04AC01, benztropine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine acetate.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Eslicarbazepine acetate.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Eslicarbazepine acetate.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Eslicarbazepine acetate.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Eslicarbazepine acetate.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Eslicarbazepine acetate.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Eslicarbazepine acetate.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Eslicarbazepine acetate.]
[A03BA03, hyoscyamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Eslicarbazepine acetate.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Eslicarbazepine acetate.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Eslicarbazepine acetate.]
[N04AA02, biperiden, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Eslicarbazepine acetate.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Eslicarbazepine acetate.]
[J05AP09, dasabuvir, The metabolism of Eslicarbazepine acetate can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Eslicarbazepine acetate.]
[N06AX11, mirtazapine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Eslicarbazepine acetate.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Eslicarbazepine acetate.]
[A03AA09, difemerine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Eslicarbazepine acetate.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Eslicarbazepine acetate.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Eslicarbazepine acetate.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Eslicarbazepine acetate.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Eslicarbazepine acetate.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Eslicarbazepine acetate.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Eslicarbazepine acetate.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Eslicarbazepine acetate.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Eslicarbazepine acetate.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Eslicarbazepine acetate.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Eslicarbazepine acetate.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Eslicarbazepine acetate.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Eslicarbazepine acetate.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Eslicarbazepine acetate.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Eslicarbazepine acetate.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Eslicarbazepine acetate.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Eslicarbazepine acetate.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Eslicarbazepine acetate.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Eslicarbazepine acetate.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine acetate.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Eslicarbazepine acetate.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Eslicarbazepine acetate.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Eslicarbazepine acetate.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Bupivacaine.]
[N07BC01, buprenorphine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Eslicarbazepine acetate.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Eslicarbazepine acetate.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Eslicarbazepine acetate.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Eslicarbazepine acetate.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Eslicarbazepine acetate.]
[R06AX09, azatadine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Eslicarbazepine acetate.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be increased when combined with Eslicarbazepine acetate.]
[R03DA08, bamifylline, Eslicarbazepine acetate may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The therapeutic efficacy of Eslicarbazepine acetate can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Eslicarbazepine acetate.]
[N06BC01, caffeine, Eslicarbazepine acetate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Oxybuprocaine.]
[J01XX08, linezolid, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Linezolid.]
[J05AE09, tipranavir, The metabolism of Eslicarbazepine acetate can be increased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be increased when combined with Eslicarbazepine acetate.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Eslicarbazepine acetate.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Eslicarbazepine acetate.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Eslicarbazepine acetate.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Eslicarbazepine acetate.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Eslicarbazepine acetate.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Eslicarbazepine acetate.]
[J05AG03, efavirenz, The metabolism of Eslicarbazepine acetate can be increased when combined with Efavirenz.]
[N04AA11, bornaprine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Eslicarbazepine acetate.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Eslicarbazepine acetate.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Eslicarbazepine acetate.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butriptyline is combined with Eslicarbazepine acetate.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Capsaicin.]
[A10BK04, ertugliflozin, The metabolism of Eslicarbazepine acetate can be decreased when combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Vinylbital.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Eslicarbazepine acetate.]
[A03AA03, camylofine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Eslicarbazepine acetate.]
[B02BX09, fostamatinib, The metabolism of Eslicarbazepine acetate can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Eslicarbazepine acetate.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be increased when combined with Eslicarbazepine acetate.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Stiripentol is combined with Eslicarbazepine acetate.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Eslicarbazepine acetate.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Eslicarbazepine acetate.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Eslicarbazepine acetate.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, Eslicarbazepine acetate may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Eslicarbazepine acetate.]
[R03BB08, revefenacin, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Eslicarbazepine acetate.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Eslicarbazepine acetate.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Eslicarbazepine acetate.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Eslicarbazepine acetate.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Eslicarbazepine acetate.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Eslicarbazepine acetate.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Eslicarbazepine acetate.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Eslicarbazepine acetate.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Eslicarbazepine acetate.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Eslicarbazepine acetate.]
[J01DD01, cefotaxime, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Eslicarbazepine acetate.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Eslicarbazepine acetate.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine acetate.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Eslicarbazepine acetate.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Eslicarbazepine acetate.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Eslicarbazepine acetate.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Eslicarbazepine acetate.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Eslicarbazepine acetate.]
[J01DB03, cephalothin, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Eslicarbazepine acetate.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Eslicarbazepine acetate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Eslicarbazepine acetate.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Eslicarbazepine acetate.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Eslicarbazepine acetate.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Eslicarbazepine acetate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be decreased when it is combined with Eslicarbazepine acetate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine acetate.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Eslicarbazepine acetate.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Eslicarbazepine acetate.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Eslicarbazepine acetate.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Eslicarbazepine acetate.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Eslicarbazepine acetate.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Eslicarbazepine acetate.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Eslicarbazepine acetate.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Eslicarbazepine acetate.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Eslicarbazepine acetate.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Eslicarbazepine acetate.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eslicarbazepine acetate.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Eslicarbazepine acetate.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Eslicarbazepine acetate.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Eslicarbazepine acetate.]
[L01AA02, chlorambucil, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Chlorambucil.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eslicarbazepine acetate.]
[A03AA08, dihexyverine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Eslicarbazepine acetate.]
[G04BD09, trospium, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Eslicarbazepine acetate.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Eslicarbazepine acetate.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Eslicarbazepine acetate.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Dyclonine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Eslicarbazepine acetate.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Eslicarbazepine acetate.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Remimazolam.]
[N07XX04, sodium oxybate, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Eslicarbazepine acetate is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Eslicarbazepine acetate.]
[N05AA01, chlorpromazine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Eslicarbazepine acetate.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Eslicarbazepine acetate.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Eslicarbazepine acetate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Eslicarbazepine acetate.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Eslicarbazepine acetate.]
[N06BA10, fenethylline, Eslicarbazepine acetate may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Eslicarbazepine acetate.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Eslicarbazepine acetate.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Trichloroethylene.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Eslicarbazepine acetate.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Eslicarbazepine acetate.]
[N06AB04, citalopram, The serum concentration of Citalopram can be increased when it is combined with Eslicarbazepine acetate.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Eslicarbazepine acetate.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Eslicarbazepine acetate.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Eslicarbazepine acetate.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Eslicarbazepine acetate.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Eslicarbazepine acetate.]
[L01EA06, asciminib, The metabolism of Eslicarbazepine acetate can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Eslicarbazepine acetate.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Eslicarbazepine acetate.]
[B06AX04, mitapivat, The metabolism of Eslicarbazepine acetate can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Eslicarbazepine acetate.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Eslicarbazepine acetate.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Eslicarbazepine acetate.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Eslicarbazepine acetate.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Eslicarbazepine acetate.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Eslicarbazepine acetate.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Eslicarbazepine acetate.]
[N05AH02, clozapine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Eslicarbazepine acetate.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Cocaine.]
[C02KB01, metyrosine, Eslicarbazepine acetate may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Eslicarbazepine acetate.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Eslicarbazepine acetate.]
[A03AB10, hexocyclium, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Eslicarbazepine acetate.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eslicarbazepine acetate.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Eslicarbazepine acetate.]
[J05AB14, valganciclovir, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Valganciclovir.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Eslicarbazepine acetate.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Eslicarbazepine acetate.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Eslicarbazepine acetate.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Eslicarbazepine acetate.]
[N03AX09, lamotrigine, The metabolism of Eslicarbazepine acetate can be increased when combined with Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Eslicarbazepine acetate can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Eslicarbazepine acetate.]
[A03AA04, mebeverine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Medifoxamine.]
[R06AD04, methdilazine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Eslicarbazepine acetate.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Melperone.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Eslicarbazepine acetate.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Eslicarbazepine acetate.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine acetate.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Eslicarbazepine acetate.]
[R06AX02, cyproheptadine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Eslicarbazepine acetate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be increased when combined with Eslicarbazepine acetate.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Eslicarbazepine acetate.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Eslicarbazepine acetate.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Niaprazine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Eslicarbazepine acetate.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Eslicarbazepine acetate.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Eslicarbazepine acetate.]
[C01CA23, theodrenaline, Eslicarbazepine acetate may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Eslicarbazepine acetate.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Escitalopram.]
[G04BD08, solifenacin, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Eslicarbazepine acetate.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Oxiracetam.]
[N04AA08, dexetimide, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Eslicarbazepine acetate.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Eslicarbazepine acetate.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Eslicarbazepine acetate.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Paroxetine.]
[B01AC04, clopidogrel, The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Eslicarbazepine acetate.]
[C04AD01, pentifylline, Eslicarbazepine acetate may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Eslicarbazepine acetate.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Eslicarbazepine acetate.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Eslicarbazepine acetate.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Cinchocaine.]
[A03AA07, dicyclomine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Pipamperone.]
[A03AB14, pipenzolate, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Eslicarbazepine acetate.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine acetate.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Eslicarbazepine acetate.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Eslicarbazepine acetate.]
[A03AB11, poldine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Eslicarbazepine acetate.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Eslicarbazepine acetate.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Eslicarbazepine acetate.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eslicarbazepine acetate.]
[J05AE08, atazanavir, The metabolism of Eslicarbazepine acetate can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eslicarbazepine acetate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Pridinol.]
[R06AB03, dimethindene, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Eslicarbazepine acetate.]
[N06BC02, propentofylline, Eslicarbazepine acetate may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Proparacaine.]
[R03DA03, proxyphylline, Eslicarbazepine acetate may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eslicarbazepine acetate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Eslicarbazepine acetate.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Eslicarbazepine acetate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Eslicarbazepine acetate.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Eslicarbazepine acetate.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Eslicarbazepine acetate.]
[C01BA03, disopyramide, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Disulfiram.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Eslicarbazepine acetate.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Eslicarbazepine acetate.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Eslicarbazepine acetate.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Eslicarbazepine acetate.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Eslicarbazepine acetate.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Eslicarbazepine acetate.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Eslicarbazepine acetate.]
[N06AA16, dothiepin, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Eslicarbazepine acetate.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Eslicarbazepine acetate.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Eslicarbazepine acetate may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Eslicarbazepine acetate.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Eslicarbazepine acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Thiopropazate.]
[G04BD01, emepronium, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Eslicarbazepine acetate.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Eslicarbazepine acetate.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Eslicarbazepine acetate.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Eslicarbazepine acetate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Eslicarbazepine acetate.]
[A03AB08, tridihexethyl, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Eslicarbazepine acetate.]
[N04AA12, tropatepine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Eslicarbazepine acetate.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Eslicarbazepine acetate.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Eslicarbazepine acetate.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Eslicarbazepine acetate.]
[N05CF02, zolpidem, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Eslicarbazepine acetate.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Eslicarbazepine acetate.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Eslicarbazepine acetate.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Eslicarbazepine acetate.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Eslicarbazepine acetate.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be increased when combined with Eslicarbazepine acetate.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Eslicarbazepine acetate.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Eslicarbazepine acetate.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Eslicarbazepine acetate.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eslicarbazepine acetate.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Eslicarbazepine acetate.]
[N04AA05, profenamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Eslicarbazepine acetate.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Eslicarbazepine acetate.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Eslicarbazepine acetate.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Eslicarbazepine acetate.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Eslicarbazepine acetate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Eslicarbazepine acetate.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Eslicarbazepine acetate.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Eslicarbazepine acetate.]
[R06AX12, terfenadine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Eslicarbazepine acetate.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Fluvoxamine.]
[M01CB01, gold sodium thiomalate, The metabolism of Eslicarbazepine acetate can be decreased when combined with Sodium aurothiomalate.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Eslicarbazepine acetate.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Eslicarbazepine acetate.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Eslicarbazepine acetate.]
[G04BD02, flavoxate, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Eslicarbazepine acetate.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Eslicarbazepine acetate.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Melitracen.]
[V03AZ01, ethanol, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Eslicarbazepine acetate.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Eslicarbazepine acetate.]
[S01BC04, flurbiprofen, The metabolism of Eslicarbazepine acetate can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Eslicarbazepine acetate.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Eslicarbazepine acetate.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Eslicarbazepine acetate is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Eslicarbazepine acetate.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Gallamine.]
[S01AD09, ganciclovir, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Eslicarbazepine acetate.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Eslicarbazepine acetate can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Eslicarbazepine acetate.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Eslicarbazepine acetate.]
[C01CA21, cafedrine, Eslicarbazepine acetate may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Eslicarbazepine acetate.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Eslicarbazepine acetate.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Eslicarbazepine acetate.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Eslicarbazepine acetate.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Eslicarbazepine acetate.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Eslicarbazepine acetate.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Eslicarbazepine acetate.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eslicarbazepine acetate.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Eslicarbazepine acetate.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Eslicarbazepine acetate.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Eslicarbazepine acetate.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Eslicarbazepine acetate.]
[P01BX01, halofantrine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Eslicarbazepine acetate.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Eslicarbazepine acetate.]
[N05AH04, quetiapine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Eslicarbazepine acetate.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Allobarbital.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Eslicarbazepine acetate.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Eslicarbazepine acetate.]
[R05DA03, hydrocodone, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Eslicarbazepine acetate.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Eslicarbazepine acetate.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Eslicarbazepine acetate.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Eslicarbazepine acetate.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Eslicarbazepine acetate.]
[L01CE01, topotecan, Eslicarbazepine acetate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The metabolism of Eslicarbazepine acetate can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Eslicarbazepine acetate.]
[A03AA30, piperidolate, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Articaine.]
[V08AB02, iohexol, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Eslicarbazepine acetate.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Eslicarbazepine acetate.]
[R06AE01, buclizine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Eslicarbazepine acetate.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Eslicarbazepine acetate.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Eslicarbazepine acetate.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Eslicarbazepine acetate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Eslicarbazepine acetate.]
[J04AC01, isoniazid, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Eslicarbazepine acetate.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Eslicarbazepine acetate.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Eslicarbazepine acetate can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The metabolism of Eslicarbazepine acetate can be decreased when combined with Deferasirox.]
[N04BC09, rotigotine, Eslicarbazepine acetate may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Nalidixic acid.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Gamolenic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Eslicarbazepine acetate.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Eslicarbazepine acetate.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Eslicarbazepine acetate.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Eslicarbazepine acetate.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Lidocaine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Eslicarbazepine acetate.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Eslicarbazepine acetate.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Eslicarbazepine acetate.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Eslicarbazepine acetate.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Eslicarbazepine acetate.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Eslicarbazepine acetate.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Eslicarbazepine acetate can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be increased when combined with Eslicarbazepine acetate.]
[N06AA21, maprotiline, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Eslicarbazepine acetate.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Eslicarbazepine acetate.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Eslicarbazepine acetate.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Eslicarbazepine acetate.]
[N03AB04, mephenytoin, The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Eslicarbazepine acetate.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Eslicarbazepine acetate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Eslicarbazepine acetate.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Eslicarbazepine acetate.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Eslicarbazepine acetate.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Eslicarbazepine acetate.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Eslicarbazepine acetate.]
[A03AB07, methantheline, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Eslicarbazepine acetate.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Eslicarbazepine acetate.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Eslicarbazepine acetate.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Eslicarbazepine acetate.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Eslicarbazepine acetate.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Eslicarbazepine acetate is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Eslicarbazepine acetate.]
[N05AA02, methotrimeprazine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Eslicarbazepine acetate.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Eslicarbazepine acetate.]
[N06BA04, methylphenidate, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Eslicarbazepine acetate.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Eslicarbazepine acetate.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Eslicarbazepine acetate.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Eslicarbazepine acetate.]
[P01AB01, metronidazole, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Metronidazole.]
[N06AX03, mianserin, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mianserin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Eslicarbazepine acetate.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Eslicarbazepine acetate.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Eslicarbazepine acetate.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be increased when combined with Eslicarbazepine acetate.]
[N06AA09, amitriptyline, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Eslicarbazepine acetate.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Eslicarbazepine acetate.]
[B02BX05, eltrombopag, The metabolism of Eslicarbazepine acetate can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Eslicarbazepine acetate.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Eslicarbazepine acetate.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Eslicarbazepine acetate.]
[R03BB01, ipratropium bromide, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Fosphenytoin.]
[N04BC04, ropinirole, Eslicarbazepine acetate may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Eslicarbazepine acetate.]
[N06BA01, amphetamine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Amphetamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Eslicarbazepine acetate.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Eslicarbazepine acetate.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Eslicarbazepine acetate.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Eslicarbazepine acetate.]
[J02AA01, amphotericin B, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Eslicarbazepine acetate.]
[C08CA04, nicardipine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Eslicarbazepine acetate.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Eslicarbazepine acetate.]
[N04BC05, pramipexole, Eslicarbazepine acetate may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Eslicarbazepine acetate.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Eslicarbazepine acetate.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Eslicarbazepine acetate.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Eslicarbazepine acetate.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Eslicarbazepine acetate.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Eslicarbazepine acetate.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Opium.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Eslicarbazepine acetate.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Eslicarbazepine acetate.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Eslicarbazepine acetate.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Eslicarbazepine acetate.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Oxypertine.]
[A03AB03, oxyphenonium, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Eslicarbazepine acetate.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.]
[M03AC01, pancuronium, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Eslicarbazepine acetate.]
[N05CC05, paraldehyde, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Eslicarbazepine acetate.]
[G04BD11, fesoterodine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Eslicarbazepine acetate.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Eslicarbazepine acetate.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Eslicarbazepine acetate.]
[C04AD03, pentoxifylline, Eslicarbazepine acetate may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Eslicarbazepine acetate.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Eslicarbazepine acetate.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Eslicarbazepine acetate.]
[N03AA02, phenobarbital, The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Eslicarbazepine acetate.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Eslicarbazepine acetate.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Eslicarbazepine acetate.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Eslicarbazepine acetate.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Eslicarbazepine acetate.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Eslicarbazepine acetate.]
[A02BX03, pirenzepine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Piritramide.]
[N02CX01, pizotyline, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Eslicarbazepine acetate.]
[J05AE03, ritonavir, The metabolism of Eslicarbazepine acetate can be increased when combined with Ritonavir.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Eslicarbazepine acetate.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Eslicarbazepine acetate.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Prilocaine.]
[N03AA03, primidone, The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Primidone.]
[M04AB01, probenecid, The metabolism of Eslicarbazepine acetate can be decreased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine acetate is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Eslicarbazepine acetate.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Eslicarbazepine acetate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eslicarbazepine acetate.]
[N04AA04, procyclidine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Eslicarbazepine acetate.]
[N05AA03, promazine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Propanidid.]
[A03AB05, propantheline, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Eslicarbazepine acetate.]
[N05CM06, propiomazine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Eslicarbazepine acetate.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Eslicarbazepine acetate.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eslicarbazepine acetate.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Eslicarbazepine acetate.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Eslicarbazepine acetate.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Eslicarbazepine acetate.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Eslicarbazepine acetate.]
[A03AB15, diphemanil, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Eslicarbazepine acetate.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Eslicarbazepine acetate.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Eslicarbazepine acetate.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Eslicarbazepine acetate.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Eslicarbazepine acetate.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Eslicarbazepine acetate.]
[J04AB02, rifampin, The metabolism of Eslicarbazepine acetate can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Eslicarbazepine acetate.]
[S01FA02, scopolamine, Eslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Eslicarbazepine acetate.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Eslicarbazepine acetate.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Eslicarbazepine acetate.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Eslicarbazepine acetate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Eslicarbazepine acetate.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Eslicarbazepine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eslicarbazepine.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Eslicarbazepine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Eslicarbazepine.]
[L01BB02, mercaptopurine, Eslicarbazepine may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Eslicarbazepine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Eslicarbazepine.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Eslicarbazepine.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Eslicarbazepine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Eslicarbazepine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Eslicarbazepine.]
[L04AX02, thalidomide, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Eslicarbazepine may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Eslicarbazepine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Eslicarbazepine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Eslicarbazepine.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Eslicarbazepine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Eslicarbazepine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Eslicarbazepine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Eslicarbazepine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Eslicarbazepine.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Eslicarbazepine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Tilidine is combined with Eslicarbazepine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Eslicarbazepine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Eslicarbazepine.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Eslicarbazepine.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eslicarbazepine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Trazodone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Eslicarbazepine.]
[A03AB12, mepenzolate, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Eslicarbazepine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Eslicarbazepine.]
[N05AA05, triflupromazine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Eslicarbazepine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Eslicarbazepine.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Eslicarbazepine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Eslicarbazepine.]
[A03BB01, butylscopolamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Eslicarbazepine.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Eslicarbazepine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Eslicarbazepine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Eslicarbazepine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Eslicarbazepine.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Eslicarbazepine.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Eslicarbazepine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Eslicarbazepine.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Eslicarbazepine.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Viloxazine is combined with Eslicarbazepine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Eslicarbazepine.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Eslicarbazepine.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Eslicarbazepine.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Eslicarbazepine.]
[J05AF01, zidovudine, The metabolism of Eslicarbazepine can be increased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Eslicarbazepine.]
[J05AE02, indinavir, The metabolism of Eslicarbazepine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Eslicarbazepine.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Eslicarbazepine.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Eslicarbazepine.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Eslicarbazepine.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Eslicarbazepine.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Eslicarbazepine.]
[G04BD07, tolterodine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be decreased when combined with Eslicarbazepine.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Eslicarbazepine.]
[S01FA01, atropine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Eslicarbazepine.]
[J01CA09, azlocillin, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Azlocillin.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Eslicarbazepine.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Eslicarbazepine.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Eslicarbazepine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Eslicarbazepine.]
[J05AE04, nelfinavir, The metabolism of Eslicarbazepine can be increased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Eslicarbazepine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Eslicarbazepine.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Eslicarbazepine.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Eslicarbazepine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Eslicarbazepine.]
[R06AC06, thonzylamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Eslicarbazepine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Eslicarbazepine.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Eslicarbazepine.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Eslicarbazepine.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Eslicarbazepine.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Eslicarbazepine.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Eslicarbazepine.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Eslicarbazepine.]
[N04AC01, benztropine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Eslicarbazepine.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Eslicarbazepine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Eslicarbazepine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Eslicarbazepine.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Eslicarbazepine.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Eslicarbazepine.]
[A03BA03, hyoscyamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Eslicarbazepine.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Eslicarbazepine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Eslicarbazepine.]
[D11AA01, glycopyrronium, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Eslicarbazepine.]
[N04AA02, biperiden, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Eslicarbazepine.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Eslicarbazepine.]
[J05AP09, dasabuvir, The metabolism of Eslicarbazepine can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Eslicarbazepine.]
[N06AX11, mirtazapine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Eslicarbazepine.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Eslicarbazepine.]
[A03AA09, difemerine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Eslicarbazepine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Eslicarbazepine.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Eslicarbazepine.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Eslicarbazepine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Eslicarbazepine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Eslicarbazepine.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Eslicarbazepine.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Eslicarbazepine.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Eslicarbazepine.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Eslicarbazepine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Eslicarbazepine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Eslicarbazepine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Eslicarbazepine.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Eslicarbazepine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Eslicarbazepine.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Eslicarbazepine.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Eslicarbazepine.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Eslicarbazepine.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Eslicarbazepine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Eslicarbazepine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Eslicarbazepine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Eslicarbazepine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Eslicarbazepine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Eslicarbazepine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Bupivacaine.]
[N07BC01, buprenorphine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Eslicarbazepine.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Eslicarbazepine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Eslicarbazepine.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Eslicarbazepine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Eslicarbazepine.]
[R06AX09, azatadine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Eslicarbazepine.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be increased when combined with Eslicarbazepine.]
[R03DA08, bamifylline, Eslicarbazepine may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The therapeutic efficacy of Eslicarbazepine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Eslicarbazepine.]
[N06BC01, caffeine, Eslicarbazepine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Oxybuprocaine.]
[J01XX08, linezolid, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Linezolid.]
[J05AE09, tipranavir, The metabolism of Eslicarbazepine can be increased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be increased when combined with Eslicarbazepine.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Eslicarbazepine.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Eslicarbazepine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Eslicarbazepine.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Eslicarbazepine.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Eslicarbazepine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Eslicarbazepine.]
[J05AG03, efavirenz, The metabolism of Eslicarbazepine can be increased when combined with Efavirenz.]
[N04AA11, bornaprine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Eslicarbazepine.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Eslicarbazepine.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Eslicarbazepine.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Eslicarbazepine.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butriptyline is combined with Eslicarbazepine.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Capsaicin.]
[A10BK04, ertugliflozin, The metabolism of Eslicarbazepine can be decreased when combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Eslicarbazepine.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Eslicarbazepine.]
[A03AA03, camylofine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Eslicarbazepine.]
[B02BX09, fostamatinib, The metabolism of Eslicarbazepine can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Eslicarbazepine.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be increased when combined with Eslicarbazepine.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Stiripentol is combined with Eslicarbazepine.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Eslicarbazepine.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Eslicarbazepine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Eslicarbazepine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Eslicarbazepine.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, Eslicarbazepine may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Eslicarbazepine.]
[R03BB08, revefenacin, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Eslicarbazepine.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Eslicarbazepine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Eslicarbazepine.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Eslicarbazepine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Eslicarbazepine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Eslicarbazepine.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Eslicarbazepine.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Eslicarbazepine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Eslicarbazepine.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Eslicarbazepine.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Eslicarbazepine.]
[J01DD01, cefotaxime, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Eslicarbazepine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Eslicarbazepine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Eslicarbazepine.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Eslicarbazepine.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Eslicarbazepine.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Eslicarbazepine.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Eslicarbazepine.]
[J01DB03, cephalothin, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Eslicarbazepine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Eslicarbazepine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Eslicarbazepine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Eslicarbazepine.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Eslicarbazepine.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Eslicarbazepine.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Eslicarbazepine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Eslicarbazepine.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Eslicarbazepine.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Eslicarbazepine.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Eslicarbazepine.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Eslicarbazepine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Eslicarbazepine.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Eslicarbazepine.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Eslicarbazepine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Eslicarbazepine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eslicarbazepine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Eslicarbazepine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Eslicarbazepine.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Eslicarbazepine.]
[L01AA02, chlorambucil, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Chlorambucil.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eslicarbazepine.]
[A03AA08, dihexyverine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Eslicarbazepine.]
[G04BD09, trospium, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Eslicarbazepine.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Eslicarbazepine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Eslicarbazepine.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Dyclonine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Eslicarbazepine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Eslicarbazepine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Eslicarbazepine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Eslicarbazepine is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Eslicarbazepine.]
[N05AA01, chlorpromazine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Eslicarbazepine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Eslicarbazepine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Eslicarbazepine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Eslicarbazepine.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Eslicarbazepine.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Eslicarbazepine.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Eslicarbazepine.]
[N06BA10, fenethylline, Eslicarbazepine may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Eslicarbazepine.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Eslicarbazepine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Eslicarbazepine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Eslicarbazepine.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Eslicarbazepine.]
[N06AB04, citalopram, Eslicarbazepine may increase the QTc-prolonging activities of Citalopram.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Eslicarbazepine.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Eslicarbazepine.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Eslicarbazepine.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Eslicarbazepine.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Eslicarbazepine.]
[L01EA06, asciminib, The metabolism of Eslicarbazepine can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Eslicarbazepine.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Eslicarbazepine.]
[B06AX04, mitapivat, The metabolism of Eslicarbazepine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Eslicarbazepine.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Eslicarbazepine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Eslicarbazepine.]
[C01EB24, mavacamten, The metabolism of Mavacamten can be decreased when combined with Eslicarbazepine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Eslicarbazepine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Eslicarbazepine.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Eslicarbazepine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Eslicarbazepine.]
[N05AH02, clozapine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Eslicarbazepine.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Cocaine.]
[C02KB01, metyrosine, Eslicarbazepine may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Eslicarbazepine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Eslicarbazepine.]
[A03AB10, hexocyclium, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Eslicarbazepine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Eslicarbazepine.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eslicarbazepine.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Eslicarbazepine.]
[J05AB14, valganciclovir, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Valganciclovir.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Eslicarbazepine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Eslicarbazepine.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Eslicarbazepine.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Eslicarbazepine.]
[N03AX09, lamotrigine, The metabolism of Eslicarbazepine can be increased when combined with Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Eslicarbazepine can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Eslicarbazepine.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Eslicarbazepine.]
[A03AA04, mebeverine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Eslicarbazepine.]
[R06AD04, methdilazine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Eslicarbazepine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Eslicarbazepine.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Eslicarbazepine.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Eslicarbazepine.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Eslicarbazepine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Eslicarbazepine.]
[R06AX02, cyproheptadine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Eslicarbazepine.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be increased when combined with Eslicarbazepine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Eslicarbazepine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Eslicarbazepine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Eslicarbazepine.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Eslicarbazepine.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Eslicarbazepine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Eslicarbazepine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Eslicarbazepine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Eslicarbazepine.]
[C01CA23, theodrenaline, Eslicarbazepine may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Eslicarbazepine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Normethadone is combined with Eslicarbazepine.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Escitalopram.]
[G04BD08, solifenacin, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Eslicarbazepine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Eslicarbazepine.]
[N04AA08, dexetimide, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Eslicarbazepine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Eslicarbazepine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Eslicarbazepine.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Eslicarbazepine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Eslicarbazepine.]
[C04AD01, pentifylline, Eslicarbazepine may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Eslicarbazepine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Eslicarbazepine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Eslicarbazepine.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dibenzepin is combined with Eslicarbazepine.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Cinchocaine.]
[A03AA07, dicyclomine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Eslicarbazepine.]
[A03AB14, pipenzolate, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Eslicarbazepine.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Eslicarbazepine.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Eslicarbazepine.]
[A03AB11, poldine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Eslicarbazepine.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Eslicarbazepine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Eslicarbazepine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eslicarbazepine.]
[J05AE08, atazanavir, The metabolism of Eslicarbazepine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eslicarbazepine.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Eslicarbazepine.]
[R06AB03, dimethindene, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Eslicarbazepine.]
[N06BC02, propentofylline, Eslicarbazepine may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Proparacaine.]
[R03DA03, proxyphylline, Eslicarbazepine may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eslicarbazepine.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Eslicarbazepine.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Eslicarbazepine.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Quinupramine is combined with Eslicarbazepine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Eslicarbazepine.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Eslicarbazepine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Eslicarbazepine.]
[C01BA03, disopyramide, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Disulfiram.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Eslicarbazepine.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Eslicarbazepine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Eslicarbazepine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Eslicarbazepine.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Eslicarbazepine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Eslicarbazepine.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Eslicarbazepine.]
[N06AA16, dothiepin, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Eslicarbazepine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Eslicarbazepine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Sibutramine.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be decreased when it is combined with Eslicarbazepine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Eslicarbazepine may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Eslicarbazepine.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Eslicarbazepine.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Eslicarbazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Eslicarbazepine.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Eslicarbazepine.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Eslicarbazepine.]
[G04BD01, emepronium, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Eslicarbazepine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Eslicarbazepine.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Toloxatone is combined with Eslicarbazepine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Eslicarbazepine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Eslicarbazepine.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Eslicarbazepine.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Eslicarbazepine.]
[A03AB08, tridihexethyl, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Eslicarbazepine.]
[N04AA12, tropatepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Eslicarbazepine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Eslicarbazepine.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Eslicarbazepine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Eslicarbazepine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Eslicarbazepine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Eslicarbazepine.]
[N05CF02, zolpidem, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Eslicarbazepine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Eslicarbazepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Eslicarbazepine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Eslicarbazepine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Eslicarbazepine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Eslicarbazepine.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be increased when combined with Eslicarbazepine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Eslicarbazepine.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Eslicarbazepine.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Eslicarbazepine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eslicarbazepine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Eslicarbazepine.]
[N04AA05, profenamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Eslicarbazepine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Eslicarbazepine.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Eslicarbazepine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Eslicarbazepine.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Eslicarbazepine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Eslicarbazepine.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Eslicarbazepine.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Eslicarbazepine.]
[R06AX12, terfenadine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Eslicarbazepine.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Fluvoxamine.]
[M01CB01, gold sodium thiomalate, The metabolism of Eslicarbazepine can be decreased when combined with Sodium aurothiomalate.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Eslicarbazepine.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Eslicarbazepine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Eslicarbazepine.]
[G04BD02, flavoxate, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Eslicarbazepine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Eslicarbazepine.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Melitracen is combined with Eslicarbazepine.]
[V03AZ01, ethanol, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Eslicarbazepine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Eslicarbazepine.]
[S01BC04, flurbiprofen, The metabolism of Eslicarbazepine can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Eslicarbazepine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Eslicarbazepine.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Eslicarbazepine.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Eslicarbazepine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Eslicarbazepine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Eslicarbazepine.]
[S01AD09, ganciclovir, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Eslicarbazepine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Eslicarbazepine.]
[C10AB04, gemfibrozil, The metabolism of Eslicarbazepine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Eslicarbazepine.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Eslicarbazepine.]
[C01CA21, cafedrine, Eslicarbazepine may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Eslicarbazepine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Eslicarbazepine.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Eslicarbazepine.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Eslicarbazepine.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Eslicarbazepine.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Eslicarbazepine.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Eslicarbazepine.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eslicarbazepine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Eslicarbazepine.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Eslicarbazepine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Eslicarbazepine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Eslicarbazepine.]
[P01BX01, halofantrine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Eslicarbazepine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Eslicarbazepine.]
[N05AH04, quetiapine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Eslicarbazepine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Eslicarbazepine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Eslicarbazepine.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Eslicarbazepine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Eslicarbazepine.]
[R05DA03, hydrocodone, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Eslicarbazepine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Eslicarbazepine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Eslicarbazepine.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Eslicarbazepine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Eslicarbazepine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Eslicarbazepine.]
[L01CE01, topotecan, Eslicarbazepine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The metabolism of Eslicarbazepine can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Eslicarbazepine.]
[A03AA30, piperidolate, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Articaine.]
[V08AB02, iohexol, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Eslicarbazepine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Eslicarbazepine.]
[R06AE01, buclizine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Eslicarbazepine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Iprindole is combined with Eslicarbazepine.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Eslicarbazepine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Eslicarbazepine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Eslicarbazepine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Eslicarbazepine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Eslicarbazepine.]
[J04AC01, isoniazid, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Eslicarbazepine.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Eslicarbazepine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Eslicarbazepine.]
[J02AB02, ketoconazole, The metabolism of Eslicarbazepine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The metabolism of Eslicarbazepine can be decreased when combined with Deferasirox.]
[N04BC09, rotigotine, Eslicarbazepine may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Nalidixic acid.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Gamolenic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Eslicarbazepine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Eslicarbazepine.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Eslicarbazepine.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Eslicarbazepine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Lidocaine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Eslicarbazepine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Eslicarbazepine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lofepramine is combined with Eslicarbazepine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Eslicarbazepine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Eslicarbazepine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Eslicarbazepine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Eslicarbazepine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Eslicarbazepine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be increased when combined with Eslicarbazepine.]
[N06AA21, maprotiline, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Eslicarbazepine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Eslicarbazepine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Eslicarbazepine.]
[P01BC02, mefloquine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Eslicarbazepine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Eslicarbazepine.]
[N03AB04, mephenytoin, The serum concentration of Eslicarbazepine can be decreased when it is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Eslicarbazepine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Eslicarbazepine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Meptazinol is combined with Eslicarbazepine.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Eslicarbazepine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Eslicarbazepine.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Eslicarbazepine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Eslicarbazepine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Eslicarbazepine.]
[A03AB07, methantheline, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Eslicarbazepine.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Eslicarbazepine.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Eslicarbazepine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Eslicarbazepine.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Eslicarbazepine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Eslicarbazepine.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Eslicarbazepine is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Eslicarbazepine.]
[N05AA02, methotrimeprazine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Eslicarbazepine.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Methylene blue is combined with Eslicarbazepine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Eslicarbazepine.]
[N06BA04, methylphenidate, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Eslicarbazepine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Eslicarbazepine.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Eslicarbazepine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Eslicarbazepine.]
[P01AB01, metronidazole, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Metronidazole.]
[N06AX03, mianserin, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Mianserin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Eslicarbazepine.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Eslicarbazepine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Eslicarbazepine.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be increased when combined with Eslicarbazepine.]
[N06AA09, amitriptyline, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Eslicarbazepine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Eslicarbazepine.]
[B02BX05, eltrombopag, The metabolism of Eslicarbazepine can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Eslicarbazepine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Eslicarbazepine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Eslicarbazepine.]
[R03BB01, ipratropium bromide, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Eslicarbazepine can be decreased when it is combined with Fosphenytoin.]
[N04BC04, ropinirole, Eslicarbazepine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Eslicarbazepine.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Eslicarbazepine.]
[N06BA01, amphetamine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Amphetamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Eslicarbazepine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Eslicarbazepine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Eslicarbazepine.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Eslicarbazepine.]
[J02AA01, amphotericin B, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Eslicarbazepine.]
[C08CA04, nicardipine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Eslicarbazepine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Eslicarbazepine.]
[N04BC05, pramipexole, Eslicarbazepine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Eslicarbazepine.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Eslicarbazepine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Eslicarbazepine.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Eslicarbazepine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Eslicarbazepine.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Eslicarbazepine.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Opipramol is combined with Eslicarbazepine.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Opium is combined with Eslicarbazepine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Eslicarbazepine.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Eslicarbazepine.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Eslicarbazepine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Eslicarbazepine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Eslicarbazepine.]
[A03AB03, oxyphenonium, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Eslicarbazepine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[M03AC01, pancuronium, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Eslicarbazepine.]
[N05CC05, paraldehyde, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Eslicarbazepine.]
[G04BD11, fesoterodine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Eslicarbazepine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Eslicarbazepine.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Eslicarbazepine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Eslicarbazepine.]
[C04AD03, pentoxifylline, Eslicarbazepine may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Eslicarbazepine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Eslicarbazepine.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Eslicarbazepine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Phenazocine is combined with Eslicarbazepine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Eslicarbazepine.]
[N03AA02, phenobarbital, The serum concentration of Eslicarbazepine can be decreased when it is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Phenoperidine is combined with Eslicarbazepine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Eslicarbazepine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Eslicarbazepine.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Eslicarbazepine can be decreased when it is combined with Phenytoin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Eslicarbazepine.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Eslicarbazepine.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Eslicarbazepine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Eslicarbazepine.]
[A02BX03, pirenzepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Piritramide is combined with Eslicarbazepine.]
[N02CX01, pizotyline, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Eslicarbazepine.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Eslicarbazepine.]
[J05AE03, ritonavir, The metabolism of Eslicarbazepine can be increased when combined with Ritonavir.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Eslicarbazepine.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Eslicarbazepine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Prilocaine.]
[N03AA03, primidone, The serum concentration of Eslicarbazepine can be decreased when it is combined with Primidone.]
[M04AB01, probenecid, The metabolism of Eslicarbazepine can be decreased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Eslicarbazepine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Eslicarbazepine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eslicarbazepine.]
[N04AA04, procyclidine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Eslicarbazepine.]
[N05AA03, promazine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Eslicarbazepine.]
[A03AB05, propantheline, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Eslicarbazepine.]
[N05CM06, propiomazine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Eslicarbazepine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Eslicarbazepine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eslicarbazepine.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Eslicarbazepine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Eslicarbazepine.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Eslicarbazepine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Eslicarbazepine.]
[A03AB15, diphemanil, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Eslicarbazepine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Eslicarbazepine.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Eslicarbazepine.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Eslicarbazepine.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Eslicarbazepine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Eslicarbazepine.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Eslicarbazepine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Eslicarbazepine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Eslicarbazepine.]
[J04AB02, rifampin, The metabolism of Eslicarbazepine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Eslicarbazepine.]
[S01FA02, scopolamine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Eslicarbazepine.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Eslicarbazepine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Eslicarbazepine.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Eslicarbazepine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Eslicarbazepine.]
